Biocartis is a molecular diagnostics company that developed the Idylla platform, a fully automated sample-to-result system for accurate and fast molecular testing. After initial proof of concept and fundraising, Biocartis gained momentum commercializing Idylla, expanding to over 50 countries through direct sales and partnerships. In 2015, Biocartis had a successful IPO, raising EUR 115 million to further develop their open platform strategy of launching 4-5 new diagnostic tests per year focused on oncology and infectious diseases. The company aims to make personalized medicine more sustainable and accessible through continuous innovation on the Idylla platform.

1. Biocartis
From inspiration to IPO
and beyond
Hilde Windels | Bolero event | 17 October 2015

2. 2
NOTICES AND WARNINGS
This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of, and should not be construed as, an
offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the
basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form
the basis of or be relied on in connection with any contract or commitment whatsoever.
The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and
amendment and such information may change materially. Unless required by applicable law or regulation, no person is under any obligation to update or keep current the
information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied,
is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any
loss howsoever arising, directly or indirectly, from this presentation or its contents.
This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's
results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements
are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results of operations, financial condition, liquidity, performance,
prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-
looking statements. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial
condition, liquidity and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements
contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are
consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods.
The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any
forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-
looking statements are based, except as required by applicable law or regulation.
This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen
or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which
would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose
possession this document comes should inform themselves about, and observe any such restrictions. The Company's shares have not been and will not be registered under the
US Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration
requirement thereof.

3. Biocartis brings innovative solutions enabling
accurate, fast and effective diagnosis,
treatment selection and treatment monitoring.
Biocartis mission statement
3

4. IdyllaTM best-in-class
• Fully automated sample-to-result
• Accurate results
• Any sample type
• Short turnaround time
• Easy to use
• Multiplexing
• Scalable
• Connectivity
4

5. From Inspiration to IPO
5

6. 6
idea
prototype
industrialisation
manufacturing
sales
IPO

8. Early history
First steps – Proof of concept and initial fundraising
• Proof of concept
for multiplexed
detection of DNA
and RNA based
biomarkers
2007 2008 2009 2010
• July 2007:
• Initial investment
EUR 67,000
• July 2008:
• Raised EUR 1.25
million
• October 2009:
• EUR 10 million
Series A financing
• Biocartis founded in
Lausanne Switzerland
• Acquired rights for
multiplex detection
platform from University
of Ghent and Tibotec-
Virco (J&J)
• First proof of
concept for
multiplexed
immunoassays
• April 2010:
• EUR 44 million
Series B financing
• Acquired tech
platform for
automated DNA /
RNA testing
(“Apollo”)
8

10. Towards commercialisation
Gaining momentum in a competitive market
• Platform renamed
Idylla™
• Ended
collaboration with
bioMérieux
2011 2012 2013 2014
• November 2011:
• EUR 58.6 million
Series C financing
• December 2012:
• EUR 34.5 million
Series D Financing
• December 2013:
• EUR 30 million
Series E financing
• Relocated research and
development to
Mechelen, Belgium
• Established pilot
manufacturing line
• Collaborations
with Philips,
Genome
Research and
Wellcome
Trust
• April 2014:
• EUR 65 million
Series F financing
• Strategic
collaboration with
Abbott Molecular
• 2010 J&J agreement
restructured to suit
both parties
10

12. 12

13. 13
GROW
Innovators
Early Adopters
Early Majority
EXPAND
SEED

14. Continued expansion global commercial footprint
• > 50 countries covered through direct and
indirect sales channels
• Direct sales force covering 16 European
countries
• Nine new distribution contracts signed in H1
2015:
– 12 additional countries
– Minimum purchase obligations > 100
IdyllaTM instruments over coming 3 years
Direct – reps on the ground
Partnership under discussion
2015/16
2016/17
2017
2016
Status as of 30 June 2015
Distributors – signed up
Distributors – under discussion
14

15. 15
IPO… the start of a marathon

16. 16

17. • IPO was in a 6.5x oversubscribed
• IPO attracted a wide interest from a mix of long-
term, specialist investors across continental
Europe, the UK and the US
• April 2015:
• EUR 115 million IPO

18. Next steps
18

19. Open platform
Launch of 4-5 assays a year
19

20. IdyllaTM menu strategy
Strategic partnerships Diagnostic app developer
partnerships
20
Oncology
Infectious Diseases

21. Our diagnostic app store
Intention to launch at least 4 to 5 assays per year
ONCOLOGYINFECTIOUS
DISEASES
2014 2015 2016 2017
KRAS (colon) NRAS (colon)
MSI
ctKRAS***
ctNRAS***
LC** (lung)
BRAF (melanoma) undisclosed assay
undisclosed assay
undisclosed assay
NRAS / BRAF (colon)NRAS / BRAF /
EGFR492 (colon)***
Ebola*
Respiratory
mixed panel
Sepsis
Influenza Virus –
Respiratory Syncytial Virus+
Influenza Virus –
Surveillance+
HIV-VL++
HBV-VL
HCV-VL

ctLC***
* Emergency Use Authorization label
** LC is the code name for an undisclosed Lung Cancer test
*** research use only
+ J&J test
++ Biocartis test in collaboration with J&J

ctBRAF***

22. We often have to remind people...
22

25. The people behind
the story are at least as
important as the
technology.
25

27. Our Biocartis DNA
• Surface tensions, think solutions
• Work hard, have fun
• Put your heart in what you do
• Take up responsibility
• Respect is an attitude
• Dare to fail
Sense - Think - Share - Do
27

28. Making personalised medicine sustainable for society

29. 29
Contact
Biocartis Investor Relations
Generaal De Wittelaan 11 B3
2800 Mechelen
Belgium
tel. +32 15 63 17 29
ir@biocartis.com
www.investors.biocartis.com